Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
72603-0105-02 72603-0105 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 21, 2019 Feb. 29, 2024 No Longer Used
00615-8391-30 00615-8391 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 11, 2021 March 31, 2024 In Use
60429-0433-05 60429-0433 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Sept. 4, 2015 March 31, 2024 In Use
70860-0205-50 70860-0205 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 31, 2017 March 31, 2024 In Use
71288-0104-10 71288-0104 Levoleucovorin calcium Levoleucovorin 50.0 mg/5mL Ancillary Therapy Chemoprotective Antidote Intravenous Aug. 22, 2019 April 30, 2024 In Use
00078-0668-15 00078-0668 Trametinib Mekinist 2.0 mg/1 Chemotherapy MEK Inhibitor BRAF Oral March 17, 2016 April 30, 2024 In Use
00574-0930-10 00574-0930 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 25, 2021 April 30, 2024 In Use
00574-0931-25 00574-0931 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 25, 2021 April 30, 2024 In Use
51991-0890-33 51991-0890 Erlotinib Hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 April 30, 2024 In Use
63459-0177-14 63459-0177 Omacetaxine Mepesuccinate Synribo 3.5 mg/mL Chemotherapy Plant Alkaloid BCR-ABL Subcutaneous Nov. 19, 2012 April 30, 2024 In Use
70860-0203-50 70860-0203 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 April 30, 2024 In Use
63629-9530-01 63629-9530 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 12, 2022 April 30, 2024 In Use
63629-9531-01 63629-9531 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 22, 2022 April 30, 2024 In Use
70860-0215-68 70860-0215 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 30, 2019 April 30, 2024 In Use
70860-0223-61 70860-0223 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous July 11, 2022 April 30, 2024 In Use
47781-0200-50 47781-0200 Melphalan USP, 2 mg Melphalan 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral March 22, 2017 May 1, 2024 In Use
63323-0319-04 63323-0319 GRANISETRON HYDROCHLORIDE Granisetron 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 20, 2009 May 31, 2024 In Use
70934-0880-21 70934-0880 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 2, 2021 May 31, 2024 In Use
00703-5075-01 00703-5075 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Aug. 27, 1998 May 31, 2024 In Use
00378-7732-93 00378-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-93 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-97 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00615-8391-05 00615-8391 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 3, 2021 June 30, 2024 In Use
00615-8391-39 00615-8391 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 3, 2021 June 30, 2024 In Use
00004-0357-30 00004-0357 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous March 29, 2011 June 30, 2024 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug. 5, 2020 June 30, 2024 In Use
00591-5019-02 00591-5019 Fulvestrant Fulvestrant 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 22, 2019 June 30, 2024 In Use
67457-0886-05 67457-0886 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 250.0 mg/mL Hormonal Therapy Progestin Intramuscular Sept. 22, 2017 June 30, 2024 In Use
70934-0148-10 70934-0148 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 16, 2019 June 30, 2024 In Use
00615-8395-05 00615-8395 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 27, 2021 July 31, 2024 In Use
00615-8395-30 00615-8395 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 4, 2021 July 31, 2024 In Use
00615-8395-39 00615-8395 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 27, 2021 July 31, 2024 In Use
60687-0636-01 60687-0636 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 20, 2022 July 31, 2024 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 July 31, 2024 In Use
00069-3033-20 00069-3033 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 July 31, 2024 In Use
70860-0783-10 70860-0783 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 15, 2021 July 31, 2024 In Use
00574-0866-10 00574-0866 Cyclosporine Cyclosporine 50.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Intravenous Oct. 7, 2003 Aug. 1, 2024 In Use
49884-0289-01 49884-0289 Megestrol Acetate Megestrol Acetate 20.0 mg/1 Hormonal Therapy Progestin Analog Oral Aug. 8, 1988 Aug. 31, 2024 In Use
52584-0047-25 52584-0047 Methylprednisolone Sodium Succinate Solu-Medrol 125.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Oct. 25, 2016 Aug. 31, 2024 In Use
51991-0942-98 51991-0942 Dexrazoxane Hydrochloride Dexrazoxane 500.0 mg/50mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous June 26, 2017 Aug. 31, 2024 In Use
60687-0647-01 60687-0647 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 20, 2022 Aug. 31, 2024 In Use
00054-8550-25 00054-8550 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 1, 1994 Aug. 31, 2024 In Use
45963-0611-59 45963-0611 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 5, 2015 Aug. 31, 2024 In Use
59148-0046-70 59148-0046 Decitabine Dacogen 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 2, 2006 Aug. 31, 2024 In Use
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2018 Aug. 31, 2024 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2020 Aug. 31, 2024 In Use
70860-0218-10 70860-0218 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 21, 2021 Aug. 31, 2024 In Use
49884-0290-04 49884-0290 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Aug. 8, 1988 Sept. 30, 2024 In Use
00781-9253-94 00781-9253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 27, 2014 Sept. 30, 2024 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct. 24, 2018 Sept. 30, 2024 In Use

Found 10,000 results in 6 millisecondsExport these results